190 related articles for article (PubMed ID: 34373039)
1. Evaluation of outcome measures for myasthenia gravis subgroups.
Luo Y; Dong X; Peng Y; Cui B; Yan C; Jin W; Li Y; Zhou R; Huang K; Yang H
J Clin Neurosci; 2021 Sep; 91():270-275. PubMed ID: 34373039
[TBL] [Abstract][Full Text] [Related]
2. Correlation of Quantitative Myasthenia Gravis and Myasthenia Gravis Activities of Daily Living scales in the MGTX study.
McPherson T; Aban I; Duda PW; Farzaneh-Far R; Wolfe GI; Kaminski HJ; Cutter G; Lee I;
Muscle Nerve; 2020 Aug; 62(2):261-266. PubMed ID: 32369631
[TBL] [Abstract][Full Text] [Related]
3. Validation of Spanish version of 15-item myasthenia gravis quality-of-life questionnaire.
Contreras JP; Salinas R; Vidal C; Hoffmeister L; Wolfe GI; Cea G
Acta Neurol Scand; 2021 Nov; 144(5):546-552. PubMed ID: 34131909
[TBL] [Abstract][Full Text] [Related]
4. Gender differences in clinical outcomes in myasthenia gravis: A prospective cohort study.
Thomsen JLS; Vinge L; Harbo T; Andersen H
Muscle Nerve; 2021 Nov; 64(5):538-544. PubMed ID: 34036597
[TBL] [Abstract][Full Text] [Related]
5. QMG and MG-ADL correlations: Study of eculizumab treatment of myasthenia gravis.
Howard JF; Freimer M; O'Brien F; Wang JJ; Collins SR; Kissel JT;
Muscle Nerve; 2017 Aug; 56(2):328-330. PubMed ID: 28010051
[TBL] [Abstract][Full Text] [Related]
6. Validity, reliability, and sensitivity to change of the myasthenia gravis activities of daily living profile in a sample of Italian myasthenic patients.
Raggi A; Antozzi C; Baggi F; Leonardi M; Maggi L; Mantegazza R
Neurol Sci; 2017 Nov; 38(11):1927-1931. PubMed ID: 28780706
[TBL] [Abstract][Full Text] [Related]
7. Translation and validation of the arabic version of the myasthenia gravis activities of daily living scale.
Alanazy MH; Abuzinadah AR; Muayqil T
Muscle Nerve; 2019 May; 59(5):583-586. PubMed ID: 30697753
[TBL] [Abstract][Full Text] [Related]
8. Efgartigimod and Ravulizumab for Treating Acetylcholine Receptor Auto-antibody-Positive (AChR-Ab+) Generalized Myasthenia Gravis: Indirect Treatment Comparison.
van Steen C; Celico L; Spaepen E; Hagenacker T; Meuth SG; Ruck T; Smith AG; Bodicoat DH; de Francesco M; Iannazzo S
Adv Ther; 2024 Jun; 41(6):2486-2499. PubMed ID: 38642198
[TBL] [Abstract][Full Text] [Related]
9. Reliability and Validity of Turkish Myasthenia Gravis-Activities of Daily Living Scale.
Karanfil E; Salcı Y; Fil-Balkan A; Bekircan-Kurt CE; Erdem Özdamar S; Armutlu K
OTJR (Thorofare N J); 2021 Apr; 41(2):101-107. PubMed ID: 33016212
[TBL] [Abstract][Full Text] [Related]
10. Myasthenia Gravis Impairment Index: Sensitivity for Change in Generalized Muscle Weakness.
de Meel RHP; Barnett C; Bril V; Tannemaat MR; Verschuuren JJGM
J Neuromuscul Dis; 2020; 7(3):297-300. PubMed ID: 32250313
[TBL] [Abstract][Full Text] [Related]
11. Effect of efgartigimod on muscle group subdomains in participants with generalized myasthenia gravis: post hoc analyses of the phase 3 pivotal ADAPT study.
Bril V; Howard JF; Karam C; De Bleecker JL; Murai H; Utsugisawa K; Ulrichts P; Brauer E; Zhao S; Mantegazza R; Vu T;
Eur J Neurol; 2024 Jan; 31(1):e16098. PubMed ID: 37843174
[TBL] [Abstract][Full Text] [Related]
12. The myasthenia gravis--specific activities of daily living profile.
Muppidi S
Ann N Y Acad Sci; 2012 Dec; 1274():114-9. PubMed ID: 23252905
[TBL] [Abstract][Full Text] [Related]
13. Physician- and self-assessed myasthenia gravis activities of daily living score.
Lee HL; Min JH; Seok JM; Cho EB; Cho HJ; Kim YD; Kim BJ
Muscle Nerve; 2018 Mar; 57(3):419-422. PubMed ID: 28796382
[TBL] [Abstract][Full Text] [Related]
14. The use of eculizumab in ventilator-dependent myasthenia gravis patients.
Usman U; Chrisman C; Houston D; Haws CC; Wang A; Muley S
Muscle Nerve; 2021 Aug; 64(2):212-215. PubMed ID: 34008175
[TBL] [Abstract][Full Text] [Related]
15. Depression: A Contributing Factor to the Clinical Course in Myasthenia Gravis Patients.
Mihalache OA; Vilciu C; Petrescu DM; Petrescu C; Manea MC; Ciobanu AM; Ciobanu CA; Popa-Velea O; Riga S
Medicina (Kaunas); 2023 Dec; 60(1):. PubMed ID: 38256317
[No Abstract] [Full Text] [Related]
16. Long-term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses.
Howard JF; Karam C; Yountz M; O'Brien FL; Mozaffar T;
Ann Clin Transl Neurol; 2021 Jul; 8(7):1398-1407. PubMed ID: 34043280
[TBL] [Abstract][Full Text] [Related]
17. Translation and validation of the Myasthenia Gravis Activities of Daily Living Questionnaire: Latvian version.
Grosmane A; Roze I; Roddate M; Ķauķe G; Žukova V; Glāzere I; Zolovs M; Ķēniņa V
Front Neurol; 2024; 15():1397603. PubMed ID: 38859974
[TBL] [Abstract][Full Text] [Related]
18. Disease Severity Assessment and Short-Term Outcome in Patients with Myasthenia Gravis.
Vemuri D; Garuda BR; Gopi S; Kumar TS; Kumari UA
Ann Indian Acad Neurol; 2020; 23(2):215-219. PubMed ID: 32189865
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of ravulizumab in patients with generalized myasthenia gravis by time from diagnosis: A post hoc subgroup analysis of the CHAMPION MG study.
Howard JF; Vu T; Mantegazza R; Kushlaf H; Suzuki S; Wiendl H; Beasley KN; Liao S; Meisel A;
Muscle Nerve; 2024 May; 69(5):556-565. PubMed ID: 38380691
[TBL] [Abstract][Full Text] [Related]
20. Measuring treatment adverse event burden in myasthenia gravis: Single-center prospective evaluation utilizing the Adverse Event Unit (AEU).
Hehir MK; Conaway M; St Sauveur AB; Feb K; Kolb NA; Waheed W; McNeish BL; Tweedy N; Burns TM
Muscle Nerve; 2024 Jan; 69(1):32-39. PubMed ID: 37676119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
